PRESS RELEASE

For Immediate Release

Contact: info@globalcancertechnology.com

Global Cancer Technology's GCT-007 receives promising pre-clinical results from the University of Colorado Anschutz Medical School

Direct comparison to Paxalisib™ in glioblastoma shows GCT-007 to be more effective at lower concentrations

San Diego, CA, March 13, 2024—Global Cancer Technology (GCT) is pleased to announce promising pre-clinical results comparing its novel and proprietary PI3 Kinase inhibitor, GCT-007, with Paxalisib,™, a brain penetrant PI3Kinase inhibitor currently in clinical trials for the treatment of glioblastoma. The concern with this class of PI3K inhibitors has been systemic toxicity at the current dosing regimen. Based on the distinct mechanism by which GCT-007 causes an increase in critical immune structures, the experiment compared GCT-007 with Paxalisib™ to determine if GCT007 could be used at lower concentrations because of its effect on important immune structures, including PD-L1.

Dr. Richard Tobin and his team from CU Anschutz Medical School, Department of Surgery, performed the experiments. The *in vitro* experiments showed that GCT-007 was more effective at increasing important immune markers at lower concentrations than Paxalisib™.

"We are delighted to see the direct comparison of GCT-007 with Paxalisib™ in this pre-clinical study of GBM and look forward to continuing our productive and exciting collaboration with Dr. Tobin," said Dr. M. Karen Newell Rogers, chief scientific consultant for GCT.

John Clark, the CEO of Global Cancer Technology, added, "This is another significant milestone for GCT-007 as it continues to produce impressive pre-clinical data in glioblastoma trials."

---

*Global Cancer Technology is a pre-clinical non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial {**globalcancertechnology.com**}. Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.*